Literature DB >> 27665023

Natural killer cells in malignant hematology: A primer for the non-immunologist.

Geoffrey S Kannan1, Arianexys Aquino-Lopez2, Dean A Lee3.   

Abstract

Natural killer cells were first described over 40years ago, but the last 15years has shown tremendous progress in our understanding of their biology and our ability to manipulate them for clinical therapeutic effect. Despite the increased understanding by clinicians and scientists investigating these cells, their biology remains a confusing subject for many because of the wide array of receptors, complex interactions, multiple models of predicting function, and contradictory data in the literature. While they are microscopically indistinguishable from T cells and share many of the same effector functions, their mechanisms of target recognition are completely distinct from yet complimentary to T cells. In this review we provide a basic understanding of NK cell biology and HLA recognition as compared and contrasted to T cells using a metaphor of border patrol and passports. We conclude with a summary of the evidence for NK cell effects in hematologic malignancies and describe new advances in NK cell immunotherapy aimed at improving these effects.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adoptive immunotherapy; Cytotoxicity; Graft-vs-leukemia; Hematopoietic stem cell transplantation; KIR mismatch; Natural killer cells

Mesh:

Year:  2016        PMID: 27665023     DOI: 10.1016/j.blre.2016.08.007

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  7 in total

Review 1.  Natural Killer Cells: the Missing Link in Effective Treatment for High-Grade Serous Ovarian Carcinoma.

Authors:  Morgan Pugh-Toole; Anna P Nicolela; Sarah Nersesian; Brendan M Leung; Jeanette E Boudreau
Journal:  Curr Treat Options Oncol       Date:  2022-02-22

2.  Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.

Authors:  Hemalatha G Rangarajan; Marcelo S F Pereira; Ruta Brazauskas; Andrew St Martin; Ashleigh Kussman; Ezgi Elmas; Michael R Verneris; Shahinaz M Gadalla; Steven G E Marsh; Sophie Paczesny; Stephen R Spellman; Stephanie J Lee; Dean A Lee
Journal:  Transplant Cell Ther       Date:  2021-08-15

3.  Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma.

Authors:  Soumen Khatua; Laurence J N Cooper; David I Sandberg; Leena Ketonen; Jason M Johnson; Michael E Rytting; Diane D Liu; Heather Meador; Prashant Trikha; Robin J Nakkula; Gregory K Behbehani; Dristhi Ragoonanan; Sumit Gupta; Aikaterini Kotrotsou; Tagwa Idris; Elizabeth J Shpall; Katy Rezvani; Rivka Colen; Wafik Zaky; Dean A Lee; Vidya Gopalakrishnan
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

Review 4.  Natural Killer Cell Immunotherapy for Osteosarcoma.

Authors:  Brian P Tullius; Buhvana A Setty; Dean A Lee
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 5.  Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.

Authors:  Sarah Nersesian; Haley Glazebrook; Jay Toulany; Stephanie R Grantham; Jeanette E Boudreau
Journal:  Front Immunol       Date:  2019-08-09       Impact factor: 7.561

6.  Salmonella Immunotherapy Improves the Outcome of CHOP Chemotherapy in Non-Hodgkin Lymphoma-Bearing Mice.

Authors:  Thais Bascuas; María Moreno; Sofía Grille; José A Chabalgoity
Journal:  Front Immunol       Date:  2018-01-23       Impact factor: 7.561

7.  MRI-guided interventional natural killer cell delivery for liver tumor treatment.

Authors:  Zhanliang Su; Xifu Wang; Linfeng Zheng; Tianchu Lyu; Matteo Figini; Bin Wang; Daniel Procissi; Junjie Shangguan; Chong Sun; Liang Pan; Lei Qin; Bin Zhang; Yury Velichko; Riad Salem; Vahid Yaghmai; Andrew C Larson; Zhuoli Zhang
Journal:  Cancer Med       Date:  2018-03-30       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.